Our Science
World-leading capabilities in multiplexable gene editing
Genome editing for immune-privileged features
Press Releases
Qihan Biotech Raises Additional USD 67 Million in Series A++ Financing. Funds to Advance Pipeline of Novel Cell and Organ Therapies
Qihan Biotech Co. Ltd announced today that it has raised an additional $67 million in Series A++ financing. With these investments, Qihan’s total Series A financing raised to date has exceeded $100 million.
1 / 3
Press Releases
Qihan Biotech Publishes First Clinical Xenotransplantation Prototype, ‘Pig 3.0’, in Nature Biomedical Engineering
In a leap forward for immune privileged cell and organ therapy, researchers create first clinical xenotransplantation prototype with enhanced human immune compatibility and without active porcine endogenous retrovirus (PERV).
1 / 3
Press Releases
Co-founder Dr. George Church visited Qihan to lead SAB meetings
On October 23, 2019, Dr. George Church visited Qihan, and he learned about the team’s research progress and gave a scientific speech on cutting-edge gene-editing technology.
1 / 3
Join Our Team
Contact Us
Address: Xiaoshan District, Hangzhou, Zhejiang, China
Zipcode: 311231
TEL: 0571-83500380
FAX: 0571-83500370